Ammonul Approval History
- FDA approved: Yes (First approved February 17th, 2005)
- Brand name: Ammonul
- Generic name: sodium benzoate and sodium phenylacetate
- Company: Medicis
- Treatment for: Hyperammonemia
Ammonul (sodium benzoate and sodium phenylacetate) is indicated as an adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.
Development History and FDA Approval Process for Ammonul
|Feb 17, 2005||Ammonul Medicis - Treatment for Urea Cycle Disorder|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.